R Squared LTD Esperion Therapeutics, Inc. Transaction History
R Squared LTD
- $214 Billion
- Q4 2025
A detailed history of R Squared LTD transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, R Squared LTD holds 15,173 shares of ESPR stock, worth $44,001. This represents 0.03% of its overall portfolio holdings.
Number of Shares
15,173
Previous 12,283
23.53%
Holding current value
$44,001
Previous $32.6 Million
72.47%
% of portfolio
0.03%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ESPR
# of Institutions
220Shares Held
115MCall Options Held
643KPut Options Held
769K-
Vanguard Group Inc Valley Forge, PA14.9MShares$43.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY14MShares$40.6 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY9.75MShares$28.3 Million0.51% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT7.06MShares$20.5 Million0.1% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$19.4 Million7.68% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $193M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...